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Abstract
Background—Resistant hypertension (RH) is a growing health burden in this country affecting 
as many as one in five adults being treated for hypertension. RH is associated with increased risk 
of adverse cardiovascular disease (CVD) events and all-cause mortality. Strategies to reduce blood 
pressure in this high risk population are a national priority.
Methods—TRIUMPH is a single site, prospective, randomized clinical trial (RCT) to evaluate 
the efficacy of a center-based lifestyle intervention consisting of exercise training, reduced sodium 
and calorie DASH eating plan, and weight management compared to standardized education and 
physician advice in treating patients with RH. Patients (N=150) will be randomized in a 2:1 ratio 
to receive either a 4-month supervised lifestyle intervention delivered in the setting of a cardiac 
rehabilitation center or to a standardized behavioral counseling session to simulate real-world 
medical practice. The primary end point is clinic blood pressure; secondary endpoints include 
ambulatory blood pressure and an array of CVD biomarkers including left ventricular 
hypertrophy, arterial stiffness, baroreceptor reflex sensitivity, insulin resistance, lipids, 
sympathetic nervous system activity, and inflammatory markers. Lifestyle habits, blood pressure 
and CVD risk factors also will be measured at one year follow-up.
Conclusions—The TRIUMPH randomized clinical trial (ClinicalTrials.gov NCT02342808) is 
designed to test the efficacy of an intensive, center-based lifestyle intervention compared to a 
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standardized education and physician advice counseling session on blood presssure and CVD 
biomarkers in patients with RH after 4 months of treatment, and will determine whether lifestyle 
changes can be maintained for a year.
Keywords
Resistant hypertension; DASH diet; exercise; obesity; cardiac rehabilitation
BACKGROUND
The term “resistant hypertension” (RH) is defined as blood pressure (BP) that remains above 
goal (e.g., systolic blood pressure [SBP]>140 mm Hg and/or diastolic blood pressure 
[DBP]>90 mm Hg), despite adherence to a regimen of 3 or more optimally-dosed 
antihypertensive medications of different classes, one of which is a diuretic, or the need for 
4 or more antihypertensive agents to achieve goal.1 With the growing prevalence of 
hypertension in this country, RH is a major public health concern, affecting more than 7.5 
million Americans.1-3 Patients with RH are 50% more likely to experience a cardiovascular 
(CVD) event, including stroke, kidney failure, myocardial infarction, and death, compared 
to patients with controlled BP.4-10 There is an urgent need for developing RH management 
strategies to lower BP as well as to reduce the high risk of CVD-related events.11
Lifestyle modifications, including exercise training and dietary modification, are of proven 
efficacy in lowering BP in unmedicated patients with hypertension and are often 
recommended as the first step for treating high BP.12 The Dietary Approaches to Stop 
Hypertension (DASH) diet has been shown to lower BP in hypertensive patients who are not 
treated with drugs.13-18 Moreover, when the DASH diet is combined with exercise and 
caloric restriction, even greater, and quite marked, BP reductions can be achieved.19,20 
However, the efficacy of these lifestyle modifications in RH patients who are refractory to 
medical therapy is unknown.
In a recent editorial, Hayward and Krumholz21 provide a compelling argument that 
treatment decisions should be made on the basis of patients’ overall CVD risk status, with 
the objective of lowering this risk as much as possible. Effective lifestyle interventions 
afford the opportunity for not only reduction of BP, but also for modification of multiple 
risk factors, which can result in significant reduction of overall CVD risk in RH patients. 
Patient-centered outcomes, including quality of life, may also improve with lifestyle 
modifications. A premise of the TRIUMPH trial is that unhealthy lifestyles, including poor 
food choices and sedentary living, play an important role in the development and persistence 
of RH and that modifying these unhealthy behaviors will arrest and potentially reverse the 
disease process. A further premise is that despite the apparent motivation of patients to adopt 
a healthy lifestyle, a structured intervention program is needed for them to achieve and 
maintain a therapeutic response. Unhealthy behavior patterns are typically well-entrenched 
and have long-term rather than short-term negative consequences, and lifestyle changes 
require a significant daily commitment to effortful planning and recalibration of life 
priorities. Figure 1 depicts a model by which poor nutrition and lack of exercise may 
adversely impact BP in this population, and how the complex interplay of autonomic, 
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metabolic, inflammatory, cardiac, and vascular function may be both a cause and 
consequence of RH.
Novel Invasive Approaches to the Treatment of Resistant Hypertension
The failure of treatment with antihypertensive drugs to adequately lower BP in RH patients 
has prompted the development of novel non-pharmacological interventions. One approach is 
carotid baroreceptor activation to attenuate sympathetic activity and augment cardiac vagal 
control.22,23 Although this technique has been successful at achieving modest reductions in 
BP in early clinical trials, it requires permanent implantation of a device and approximately 
25% of patients may experience procedure-related adverse outcomes.24,25 Recently, a small, 
open-label randomized trial of a central iliac arteriovenous anastomosis produced with a 
coupler device demonstrated significant reductions in both SBP and DBP, but much remains 
to be learned about the longer term efficacy and safety of this intervention. 26 Another 
initially promising procedural approach to the treatment of RH is catheter-based renal 
sympathetic denervation.27 The SYMPLICITY HTN-2 trial28 generated much excitement in 
the medical community by suggesting that percutaneous renal sympathetic denervation 
could lower clinic SBP by as much as 30 mm Hg in RH patients.29 However, SYMPLICITY 
HTN-3,30 a more rigorously designed and pivotal multi-center trial of catheter-based renal 
denervation performed in the United States, failed to meet its primary efficacy endpoint of a 
reduction in clinic-based SBP ≥5 mm Hg. This disappointing outcome has tempered the 
prospects for widespread utilization of renal denervation in the management of RH in the 
near future, and underscores the need for new avenues of investigation for non-
pharmacological approaches to lowering BP and reducing CVD risk in RH patients.
Back to the Future: Potential Benefits of Lifestyle Modification in Patients with Resistant 
Hypertension
Although the value of lifestyle interventions in patients already taking antihypertensive 
medications has not been widely studied, the available evidence, acquired primarily in 
patients treated with 1 or 2 drugs, appears promising. Regular exercise alone lowered DBP 
and led to regression of left ventricular hypertrophy (LVH) in a small study of medicated 
African-American men with uncontrolled hypertension,31 and the TONE study 
demonstrated that in elderly patients receiving antihypertensive monotherapy, sodium 
restriction and weight loss resulted in improved BP control.32 Surprisingly, there are limited 
data describing the effects of the DASH diet in medicated hypertensive patients. In a study 
of 55 hypertensive patients treated with an angiotensin receptor blocker (ARB), the DASH 
diet was associated with a 5 mm Hg greater reduction in ambulatory SBP compared to 
patients taking the ARB with their usual diet.33 The ADAPT trial34 was an Australian study 
of hypertensive patients treated with 1 or 2 drugs in which an intervention designed to 
promote consumption of a modified DASH diet resulted in a modest (4/2 mm Hg), but 
statistically significant, reduction in ambulatory BP and reduced dependence on 
antihypertensive medications. In the DEW-IT study,35 a 9-week ‘feeding’ study of 44 
overweight adults on a single BP-lowering agent, the DASH diet coupled with weight loss 
also resulted in significant BP reductions.
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Surprisingly, lifestyle modification has not been rigorously evaluated in patients with RH. 
Several small studies, however, suggest that changes in diet and physical activity have the 
potential to lower BP substantially in these individuals. For example, in a study of 12 
subjects with RH, 24-hour ambulatory BP was 23/9 mm Hg lower on a 50 mmol/d (1150 
mg/d) sodium diet compared to a 250 mmol/d (5750 mg/d) sodium diet.36 In this study, 
however, the treatment periods were short (7 days) and all food was prepared in a clinical 
research center; whether similar results could be achieved in the longer-term and in the 
absence of specially prepared meals is unclear. In another small study, Dimeo et al.37 
examined the value of physical activity in 50 patients with RH who were randomized to 
thrice weekly treadmill exercise or a control condition; exercise decreased ambulatory 
daytime BP by 6/3 mm Hg. Thus, preliminary evidence suggests that lifestyle modifications 
may be effective in in reducing BP in RH patients, but such efforts need to be examined in 
more rigorous RCTs.
METHODS
TRIUMPH is a randomized controlled trial (RCT) designed to evaluate whether an 
intensive, medically-supervised lifestyle intervention can achieve clinically significant BP 
lowering in medicated patients with RH. In addition to evaluating the primary endpoint of 
clinic BP, the study will also examine effects on 24-hour ambulatory blood pressure (ABP), 
along with a constellation of CVD risk factors that are common in RH patients and that 
contribute to the increased risk associated with uncontrolled BP.
One hundred fifty patients with RH will be evaluated and randomized with 2:1 allocation to 
one of two treatment groups: (1) Center-based Lifestyle Intervention (C-LIFE) or (2) 
Standardized Education and Physician Advice (SEPA). Participants will be evaluated at (a) 
baseline; (b) after a 4-month intervention; and (c) 1 year after randomization. The study 
design is depicted in Figure 2.
Participants
RH is defined as SBP that is higher than 140 mm Hg, despite treatment with ≥3 optimally-
dosed antihypertensive medications of different classes, including a diuretic,12 or the need 
for 4 or more drugs to achieve a SBP ≤ 140 mmHg.
Inclusion Criteria—Recruitment will target individuals with documented RH within the 
last 6 months. Individuals treated for two or more weeks with at least 3 antihypertensive 
medications of different classes (at a stable dosage), including a diuretic, with clinic SBP ≥ 
140 mm Hg or DBP ≥ 90 mm Hg, will be eligible. Individuals being treated with 4 or more 
antihypertensive medications (including a diuretic) with SBP ≥ 130 or DBP ≥ 85 mm Hg 
also will be eligible. In addition to hypertension, other inclusion criteria include: overweight 
or obese (e.g., body mass index [BMI] 25-39.9 kg/m2), sedentary (exercise <30 min/week), 
age 35-80 years, and willingness to be randomized to either of the 2 treatment groups.
Exclusion criteria—Secondary hypertension, severe chronic kidney disease defined as an 
estimated glomerular filtration rate [GFR] <45 ml/min/1.73m2, moderate-severe ischemic 
heart disease (Canadian Cardiovascular Society Class 3 or 4 angina or evidence of ischemia 
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at <85% heart rate reserve on treadmill testing), severe heart failure (New York Heart 
Association Class 3 or 4), high grade arrhythmias, severe valvular heart disease, severe 
asthma or chronic obstructive lung disease, diabetes requiring insulin, musculoskeletal or 
neurologic problems that would preclude participation in aerobic exercise training, current 
major psychiatric disorder or active drug abuse, current alcohol consumption >14 drinks/
week, prior gastric bypass surgery, a life-limiting comorbid medical condition such as 
cancer, or ‘pseudoresistant’ hypertension due to medication non-adherence or due to the 
white coat effect.38
Screening Procedures to Determine Eligibility for the TRIUMPH Trial
All eligible patients will undergo clinic blood pressure and medical screening, physical 
examination, and body weight assessment. Blood pressure will be determined according to 
JNC 7 guidelines.39 Screening assessments also will include measures of serum creatinine 
and eGFR, electrolytes, HbA1c, and urinary albumin/creatinine ratio to screen for secondary 
hypertension and other conditions that would preclude patients from safely participating in 
the study and to assess comorbidities and target organ manifestations of hypertension. The 
most common causes of secondary hypertension are CKD and primary hyperaldosteronism. 
All patients will have baseline measurements of serum creatinine to assess renal function, 
and renin and aldosterone levels to exclude primary hyperaldosteronism. Thyroid 
stimulating hormone will be measured to exclude clinically significant thyroid disorders. We 
will not screen for other secondary causes of hypertension because these conditions tend to 
be rare (e.g., pheochromocytoma) and/or the impact of current therapies are inconclusive or 
provides only marginal BP lowering benefit (e.g., renovascular disease and obstructive sleep 
apnea).
Medication Reconciliation—Treatment regimens will be documented by having 
participants bring their actual medications to the research clinic and confirmed with 
referring physicians. To facilitate assessment of medication changes, the intensity of therapy 
will be quantified as the Daily Defined Dose (DDD) using a method developed by the World 
Health Organization. The DDD is a system for quantification of drug amount designed to 
enable comparison across drug classes (e.g., 1×DDD=150 mg irbesartan or 5 mg 
amlodipine)40 and was previously used in the BP Guide and TASMIN-SR studies.41,42
Medication Adherence Screening—Because patients who are non-adherent to their 
antihypertensive medications could be erroneously classified as RH, we will perform an 
initial screen for medication adherence using the Morisky Medication Adherence 
Measure.43 This 8-item scale was developed from the well-validated and widely-used 4-item 
version44 with the objective of specifically evaluating medication adherence in patients with 
hypertension. The scale has established reliability and validity45 and is related to BP control, 
with a score ≥ 3 identifying patients with poor BP control due to non-adherence with a 
sensitivity of 93%.43
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Participants will be randomized to one of two treatment arms and encouraged to maintain 
their prescribed antihypertensive medications at the discretion of their personal physicians, 
unless contraindicated by safety issues.
(1) Center-based Lifestyle Intervention (C-LIFE): The 4-month C-LIFE intervention 
will consist of 4 components delivered by our research staff at participating community 
CR centers:
(i) Diet: Participants will receive instruction on the DASH diet with caloric and 
sodium restriction (2300 mg/day) and feedback on their adherence to the diet in 16 
half-hour weekly sessions. The goal of the weekly sessions is to assist participants in 
knowing how to buy and prepare the appropriate foods, to enhance their motivation to 
choose to eat those foods, and to overcome obstacles to following the diet. The 
nutritionist will utilize motivational interviewing strategies as a way to encourage 
participants to make the needed changes. A key component, used in the DASH, 
PREMIER, and ENCORE studies and incorporated into the proposed intervention, is 
motivational enhancement to reinforce commitment and confidence for behavior 
change and to help participants explore and resolve ambivalence.46,47 Specific efforts 
to provide culturally-sensitive adaptations of the diet will be provided as our prior 
work indicated that African-American participants may have difficulty adopting the 
DASH diet.48 Greater emphasis will be placed on the personal, financial, and cultural 
needs of the participants while they attempt to adopt the DASH diet and reduce 
dietary sodium (2300 mg/day), and thus provide an individually tailored intervention.
(ii) Behavioral Weight Management: The Weight Management program will consist 
of 16 half-hour weekly sessions that emphasize the initiation of eating behavior 
changes, individualized problem-solving, and strategies to facilitate the transition to a 
long-term self-care plan that is designed to prepare participants to maintain treatment 
gains on their own following termination of treatment. The weight management 
employed in TRIUMPH will include focus on the attitudes and skills needed to 
develop and implement a long-term self-care health plan.
The weight management intervention includes standard cognitive and behavioral 
strategies with a particular emphasis on the importance of self-monitoring as a 
strategy to initiate behavior change and an understanding of the roles of motivation 
for change and automaticity of behavioral patterns in maintaining behavioral changes. 
Self-monitoring of DASH food goals is used to enhance compliance with the 
recommended dietary content, and appetite monitoring is used to regulate the amount 
of food eaten. Appetite Awareness Training (AAT) serves to enhance portion control, 
facilitate reductions in caloric consumption, and reduce perceptions of deprivation by 
raising awareness of internal fullness cues. Weekly weight monitoring is to be 
continued indefinitely as small increases (which are more easily reversed) are not 
always noticeable. The weight management training will emphasize individualized 
problem-solving to remove barriers to adherence. The syllabus for the program is 
provided in an Appendix (Table S1).
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(iii) Supervised Exercise: Participants initially will exercise at one of the designated 
CR facilities 3 times per week at a level of 70-85% of their initial heart rate reserve, 
determined at the time of their baseline treadmill test.49 The exercise routine will 
consist of 10 minutes of warm up exercises, 30-45 minutes of aerobic exercise, and 
10 minutes of cool down exercises. Patients with pre-exercise SBP levels >200 mm 
Hg or DBP >110 mm Hg will not be permitted to exercise; exercise will be stopped 
immediately if patients’ SBP values exceed 250 mm Hg or DBP levels exceed 115 
mm Hg. While exercise alone has been shown to be of limited value in reducing BP50 
and in inducing weight loss,51 continued exercise and physical activity are widely 
recognized as being critically important for successful weight maintenance.52 
Therefore, participants will be counseled to develop a plan to remain active and to 
exercise on their own, using strategies previously employed to help patients transition 
from supervised to home-based exercise protocols.53,54
(iv) Maintenance: Participants will be prepared to maintain all components that 
constitute the lifestyle intervention (i.e., DASH eating plan, limited sodium 
consumption, weight management, and exercise). The C-LIFE intervention will 
emphasize the transition to self-care by carefully preparing participants to meet the 
challenges of maintaining lifestyle changes on their own. We hope to maximize the 
likelihood that those participants who show improvements with treatment will be able 
to maintain those improvements over time, especially since CR programs do not offer 
provision for long-term support for behavior change. Because patients with RH 
currently have few options to lower their BP and hypertension is a chronic disease, it 
is particularly critical to teach patients to establish a life-long self-care plan.
(2) Medical Management with Standardized Education and Physician Advice (SEPA): 
Although patients will be encouraged to achieve an ideal body weight and engage in 
exercise as part of routine counseling in primary care, no special programs will be 
provided that enhance patients’ ability to comply with these recommendations. The 
SEPA arm will consist of routine medical care provided by patients’ primary care 
physicians supplemented by an educational session on hypertension management. 
Patients will receive a dietary consultation and an individualized exercise prescription 
delivered by a health educator. In order to compare the intensive, structured C-LIFE 
program with patients’ own efforts at adhering to physician advice, patients will be free 
to engage in their own diet and exercise programs, which we will document over the 
course of the trial. Referral for an individual consultation with a nutritionist and 
exercise specialist is an option that is available to physicians in the care for patients 
with hypertension, and will be standardized at its optimal level of implementation for 
this research protocol.
Assessments
Blood pressure will be obtained in the clinic and during daily life using 24-hr ambulatory 
blood pressure monitoring (see Table 1 for assessment methods and testing schedule). In 
addition to measuring BP, we will assess an array of CVD biomarkers including left 
ventricular hypertrophy (LVH), cardiovascular hemodynamics (including cardiac output and 
systemic vascular resistance), arterial stiffness, endothelial function, baroreflex sensitivity, 
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metabolic factors such as glucose and insulin resistance, inflammatory markers, and aerobic 
capacity. We also will document the effects of the interventions on relevant lifestyle habits 
including physical activity, body weight, and diet.
In addition to better BP control, several patient-centered outcomes that could represent 
important benefits of a lifestyle intervention program will be assessed. These include 
improvements in other risk factors (e.g., hypercholesterolemia and diabetes) and overall 
CVD risk55 and improved quality of life. A detailed description of the measures obtained in 
the TRIUMPH study is available in the Appendix (Table S2).
Follow-up
Participants will be followed at 1-year post-randomization (8 months after completion of the 
4-month intervention program). All participants will be asked to report any changes in BP 
medications or other interventions to reduce BP that they may have initiated (under the care 
of their own physicians). Medication changes will be incorporated into our data analytic 
plan described below. At 1 year following randomization, measures of clinic BP, ABP, CVD 
biomarkers, body weight, dietary and exercise habits, and QoL will be reassessed. At the 
follow-up visit, patients will be asked to bring with them all medications that they are 
currently taking, so that any adjustments to their antihypertensive therapy can be 
documented. Patients will also be queried as to whether they participated in any 
supplemental programs to lose weight (including bariatric surgery), diet, or engage in 
exercise. This naturalistic follow-up has been used in prior work56-58 and yields important 
information regarding maintenance of lifestyle habits over time and will used to help 
interpret any group differences in BP and CVD biomarkers after 1 year. We also will 
document a number of clinical endpoints including cardiovascular death, non-fatal MI, non-
fatal stroke or transient ischemic attack, coronary revascularization, hospitalization for 
hypertension, angina, or heart failure, and progression to end-stage renal disease during a 
follow-up period of up to 5 years.
DATA ANALYSIS
We will evaluate the primary outcome, clinic SBP, at the immediate post-treatment 
measurement occasion (4 months), with treatment assignment (C-LIFE vs. SEPA) as a 
between subjects factor, and ethnicity, gender, age, diabetes/chronic kidney disease, baseline 
medication adherence, and pre-treatment clinic SBP as covariates, selected a priori.59 We 
will conduct an ancillary analysis in order to evaluate the possible role of change in BP 
medication on the treatment effect by adding the DDD measure as a covariate in the models 
testing treatment effects. Ambulatory daytime SBP will be evaluated as a supportive 
analysis, using the same modeling approach as above. Analysis of additional outcomes, 
including ambulatory and clinic DBP, body weight, aerobic capacity, dietary intake, LV 
mass and relative wall thickness, CVD biomarkers, and patient-centered outcomes will be 
conducted using the same modeling approach. For secondary outcomes, we again will use 
separate models for each outcome, using Benjamini and Hochberg’s60 False Discovery Rate 
correction for multiple testing. All analyses of primary and secondary outcomes will adhere 
to the intent-to-treat principle, using multiple imputation for missing data with Harrell’s 
aregImpute algorithm in R. Mediational analyses will be carried out following the bootstrap 
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procedures described by MacKinnon61 using the mediation package available in R.62 
Specifically, we will use this approach to explore the potential role of changes in aerobic 
capacity, adherence to the DASH diet, and body weight as mediators that might explain a 
treatment effect. We also will examine potential moderators of treatment by testing 
interaction terms between treatment group and background characteristics. The moderators 
of primary interest are race, age, gender, presence of kidney disease or diabetes, BRS, and 
baseline levels of BMI and physical activity. In order to reduce the chance of a Type I Error, 
we will evaluate these interactions using a pooled 2 degree of freedom test using p = .05 as 
the criterion for statistical significance.63 For the 1-year BP outcomes, we will use mixed 
models, incorporating the same covariates as in the primary analyses, but also including the 
immediate post-treatment and 1-year BP as repeated measures. All analyses will be carried 
out using SAS (Cary, NC) or R (http://cran.r-project.org/) software.
Power Analysis
The primary effect of interest is the treatment group difference in clinic SBP at 4 months. 
Power estimates were made based on the following specifications, based in part on our prior 
work with hypertensive adults13: 1) a general linear model for clinic SBP; 2) an initial 
sample size of 150 patients with 2:1 group allocation and 15% attrition at 16 weeks; 3) alpha 
of 0.05; 4) a standard deviation of 10.2 mm Hg for clinic SBP, and 13 mm Hg for the 
supportive ambulatory SBP outcome. For clinic SBP, we will have 80% power to detect 
about a 5.4 mm Hg group difference, and 90% power to detect about a 6.3 mm Hg 
difference. For ambulatory SBP, we will have 80% power to detect a group difference of 
about 6.9 mm Hg; at 90% power, we will be able to detect about an 8.1 mm Hg treatment 
difference. With respect to secondary biomarker endpoints (e.g., BRS, arterial stiffness) we 
will have 80% power to detect at least a 0.53 standard deviation difference between 
treatment groups on a given endpoint.
DISCUSSION
In order to make informed choices, patients and their providers need valid empirical 
evidence about the merits (or ‘demerits’) of structured lifestyle modification for patients 
with RH. Because the existing research is relatively sparse and was conducted primarily in 
unmedicated hypertension patients, it remains to be seen if patients with RH will be able to 
achieve significant lifestyle changes, and whether such changes will produce clinically 
significant improvements in BP control. It cannot be assumed that RH patients, who have 
complied with drug therapy yet failed to achieve target BP levels, will respond in the same 
way to lifestyle modifications as those who are not on medication. Patients who are 
refractory to medications may not achieve significant BP reductions from lifestyle changes, 
either. The value of lifestyle modification for RH patients remains an important and 
unanswered empirical question that needs to be examined in order to ascertain whether 
intensive, structured lifestyle interventions may be an effective treatment option for these 
patients. Indeed, the recently published American Heart Association and American College 
of Cardiology joint Guidelines on Lifestyle Management to Reduce Cardiovascular Risk 
noted that there is a lack of data on the effects of lifestyle modification in treated 
hypertension patients and identified this as being a priority area for future research.64 If the 
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TRIUMPH lifestyle intervention proves successful in lowering BP and if the results are 
confirmed in subsequent studies, it could be argued that third-party payers should support 
the participation of patients with RH in CR programs.
Patients with RH are typically sedentary and obese,1 so a lifestyle intervention including 
exercise, weight loss, and optimal nutrition has the potential to lower BP substantially. 
There is now good evidence that for behavior change to be successful, interventions should 
be linked to structured programs designed to facilitate behavior change.65 To date, no RCT 
has tested an intensive, structured lifestyle intervention in patients who have uncontrolled 
BP despite being on 3 or more antihypertensive medications. Also missing from the research 
literature is an examination of “moderators” of lifestyle interventions. It is important to 
determine characteristics of patients who respond to lifestyle modifications so that 
interventions can be delivered to those most likely to benefit, and so that alternative 
strategies can be developed for those unlikely to respond. TRIUMPH will examine a variety 
of possible moderators as potential individual difference measures that could affect BP 
response to lifestyle modification.
In summary, TRIUMPH is a randomized clinical trial that will test the hypothesis that an 
intensive, 4-month, cardiac rehabilitation-based lifestyle modification program to promote 
exercise, the DASH eating plan, and weight loss will result in a meaningful decrease in BP, 
improvements in other biomarkers of CVD risk, and enhanced quality of life in patients with 
RH. Moreover, we will determine if lifestyle changes can be maintained for a year. The 
results of this study will inform patients, providers, and policy makers in judging whether 
structured lifestyle interventions may be an effective treatment option for individuals with 
hypertension that is refractory to medical therapy.
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Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
ABP Ambulatory blood pressure
ARB Angiotensin receptor blocker
BMI Body Mass Index
BDI Beck Depression Inventory
BP Blood pressure
BRS Baroreflex sensitivity
C-LIFE Center-based lifestyle intervention
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DASH Dietary Approaches to Stop Hypertension
DBP Diastolic blood pressure
DDD Daily Defined Dose
EEG Electrocardiogram
GFR Glomerular filtration rate
hsCRP High-sensitivity C-reactive protein
HR Hazard Ratio
HRV Heart rate variability
IVST Interventricular septal thickness
ITT Intent to Treat
LVEDD left ventricular end-diastolic diameter
LVH Left ventricular hypertrophy
MAP Mean arterial pressure
PWT Posterior wall thickness
PWV Pulse wave velocity
QoL Quality of life
RCT Randomized clinical trial
RH Resistant hypertension
SBP Systolic blood pressure
SEPA Standardized Education and Physician Advice
STAI State-Trait Anxiety Inventory
SVR Systemic vascular resistance
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Figure 1. Conceptual Model
depicts a model by which poor dietary habits and lack of physical activity may adversely 
impact BP in this population, and how the complex interplay of autonomic, metabolic, 
inflammatory, cardiac, and vascular function may be both a cause and consequence of RH. 
The TRIUMPH study is designed primarily to evaluate whether an intensive lifestyle 
intervention delivered in a CR setting can achieve clinically significant BP lowering in 
patients whose BP has failed to be adequately controlled by the combined effects of at least 
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3 antihypertensive medications. It is also designed to provide insight into whether diet and 
exercise improve comorbid disease and associated biomarkers of CVD risk in RH patients.
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Figure 2. Study Design Overview
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Table 1
Study Outcomes, Assessment Methods and Schedule
Study Outcomes/ Endpoints Assessment Methods Timepoint
Clinical Outcomes
 Blood pressure Automated BP monitor Screening, baseline, 4M, 12M
24-hour ambulatory BP monitor Baseline, 4M, 12M
 Body weight Calibrated digital scale Screening, baseline, 4M, 12M
 Waist circumference Tape measure Baseline, 4M, 12M
Metabolic profile Fasting serum glucose, insulin and lipids Baseline, 4M, 12M
Neuroendocrine profile Serum aldosterone, plasma renin activity, 24-
hour urine catecholamines
Baseline, 4M
Kidney function Serum creatinine Screening, baseline, 4M, 12M
Urine albumin and creatinine Baseline, 4M, 12M




Echocardiography Baseline, 4M, 12M
 Arterial Stiffness Pulse wave velocity Baseline, 4M, 12M
 Baroreflex sensitivity Finometer instrument Baseline, 4M
 Estimated CVD Risk Framingham Risk Score Baseline, 4M, 12M
Aerobic Capacity Modified Balke exercise treadmill test Baseline, 4M, 12M
Physical Activity 7-day accelerometer monitoring, Community
Healthy Activities Model Program for Seniors
Activity Questionnaire
Baseline, 4M, 12M
Dietary Intake Automated Self-administered 24-hour recall, 24-
hour urine sodium, potassium, and creatinine
Baseline, 4M, 12M
Psychosocial Outcomes
 Quality of Life Short-form-36 Baseline, 4M, 12M
 Depression Beck Depression Inventory Baseline, 4M, 12M
 Anxiety State-Trait Anxiety Inventory Baseline, 4M, 12M
 Self-esteem Rosenberg Self-Esteem Scale Baseline, 4M, 12M
 Health Locus of Control Health Locus of Control Scale Baseline, 4M, 12M
Medication Adherence Morisky Adherence Scale, Medication Event
Monitoring System
Screening, baseline, 4M, 12M
Clinical Events Interview, medical record adjudication 4M, 12M and annually up to 5
yrs
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Study Outcomes/ Endpoints Assessment Methods Timepoint
 All-cause mortality, non-fatal
 myocardial infarction, stroke,
 CV-related hospitalization,
 hypertensive emergency, CV
 procedure, doubling of serum
 creatinine or end-stage renal
 disease
Note: BP= blood pressure; CV = cardiovascular; 4M= 4-months; 12M= 12-months.
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